Danielle Ortolano
@d-lano29.bsky.social
Reposted by Danielle Ortolano
I can hardly think of a better example of the moral decay in modern health care than a Goldman analyst noting that biotech cures for diseases like hepatitis are cool and all, until their success diminishes the business opportunity for pharmaceutical manufacturers.
www.cnbc.com/2018/04/11/g...
www.cnbc.com/2018/04/11/g...
Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?'
Goldman Sachs warns sales from the most successful disease treatments are difficult to maintain.
www.cnbc.com
December 19, 2024 at 11:57 PM
I can hardly think of a better example of the moral decay in modern health care than a Goldman analyst noting that biotech cures for diseases like hepatitis are cool and all, until their success diminishes the business opportunity for pharmaceutical manufacturers.
www.cnbc.com/2018/04/11/g...
www.cnbc.com/2018/04/11/g...